Editas Medicine (EDIT) Interest Expenses (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Interest Expenses of $1.4 million for Q4 2025, up 587.19% year-over-year from $203000.0 in Q4 2024, and down 41.85% quarter-over-quarter from $2.4 million in Q3 2025.
Editas Medicine (EDIT) Interest Expenses (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Interest Expenses for 11 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 587.19% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (down 65.56% YoY), while the FY2025 annual figure was $1.4 million, down 99.64% from the prior year.
- Interest Expenses declined to $1.4 million in Q4 2025 per EDIT's latest filing, from $2.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $4.0 billion in Q1 2022 and bottomed at -$7.7 million in Q4 2021.
- Historically, Interest Expenses has averaged $416.2 million across 5 years, with a median of $16.9 million in 2021.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 9023.09% — and 2024, when it plunged 98.37%.
- Editas Medicine's Interest Expenses stood at -$7.7 million in 2021, then soared by 62.83% to -$2.9 million in 2022, then jumped by 215.89% to $3.3 million in 2023, then slumped by 93.89% to $203000.0 in 2024, then surged by 587.19% to $1.4 million in 2025.
- Business Quant data shows EDIT's Interest Expenses at $1.4 million in Q4 2025, $2.4 million in Q3 2025, and $2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 203,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Mar 31, 2024 | 3.85 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 87.80 Mn |
| Sep 30, 2023 | 87.80 Mn |
| Jun 30, 2023 | 466.22 Mn |
| Jun 30, 2023 | 466.22 Mn |
| Mar 31, 2023 | 236.50 Mn |
| Mar 31, 2023 | 236.50 Mn |